scholarly journals Comparison of Serum Levels of Igf-1 and Igfbp-3 with Pharmacological Tests of Growth Hormone (Gh) Secretion in the Diagnosis of Gh Deficiency in Patients with Tumors of the Central Nervous System (Cns) in the Sell

1997 ◽  
Vol 41 (2) ◽  
pp. 300-300
Author(s):  
A Belgorosky ◽  
G Vidal ◽  
M A Rivarola
Keyword(s):  
Central Nervous System ◽  
Growth Hormone ◽  
Nervous System ◽  
Gh Deficiency ◽  
Serum Levels ◽  
Gh Secretion ◽  
Pharmacological Tests ◽  
The Central Nervous System ◽  
Igfbp 3

Localization of dopamine and its relation to the growth hormone producing cells in the central nervous system of the snail Lymnaea stagnalis

1991 ◽  
Vol 85 (1) ◽  
pp. 1-9 ◽  
Author(s):  
T. R. Werkman ◽  
J. van Minnen ◽  
P. Voorn ◽  
H. W. M. Steinbusch ◽  
B. H. C. Westerink ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Growth Hormone ◽  
Nervous System ◽  
Lymnaea Stagnalis ◽  
The Central Nervous System

scholarly journals The Role of Vitamin D in Neurodegeneration and Other Pathological Processes of the Central Nervous System

2021 ◽  
Author(s):  
Carl Nikolaus Homann
Keyword(s):  
Central Nervous System ◽  
Vitamin D ◽  
Nervous System ◽  
Human Body ◽  
Serum Levels ◽  
Nerve Cells ◽  
Pivotal Role ◽  
The Central Nervous System ◽  
Measured Response

The nervous system is the most complex organ in the human body, and it is the most essential. However nerve cells are particularly precious as, only like muscle cells, once formed, they do not replicate. This means that neural injuries cannot easily be replaced or repaired. Vitamin D seems to play a pivotal role in protecting these vulnerable and most important structures, but exactly how and to what extend is still subject to debate. Systematically reviewing the vast body of research on the influence of Vitamin D in various neuropathological processes, we found that Vitamin D particularly plays a mitigating role in the development of chronic neurodegeneration and the measured response to acutely acquired traumatic and non-traumatic nerve cells incidents. Adequate serum levels of Vitamin D before the initiation of these processes is increasingly viewed as being neuroprotective. However, comprehensive data on using it as a treatment during the ongoing process or after the injury to neurons is completed are much more ambiguous. A recommendation for testing and supplementation of insufficiencies seems to be well-founded.

scholarly journals Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
M. J. Eikelenboom ◽  
B. M. J. Uitdehaag ◽  
A. Petzold
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
Serum Levels ◽  
Disability Progression ◽  
Protein Biomarker ◽  
The Central Nervous System ◽  
Neuroaxonal Degeneration

Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed.Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH).Methods. An exploratory cross-sectional (n=51) and longitudinal (n=34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup.Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2,P<.0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P<.05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS2,P<.05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS2,P<.05).Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results.

Sign in / Sign up

Export Citation Format

Share Document